We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Adaptive Immune Cells in Ulcerative Colitis Revealed by Single-Cell Analyses

By LabMedica International staff writers
Posted on 01 Sep 2020
Print article
Image: Mass cytometry by time of flight uses CyTOF technology to enable deep profiling of translational and clinical samples across a range of cell surface and intracellular markers (Photo courtesy of University of Virginia).
Image: Mass cytometry by time of flight uses CyTOF technology to enable deep profiling of translational and clinical samples across a range of cell surface and intracellular markers (Photo courtesy of University of Virginia).
Inflammatory bowel disease encompasses a spectrum of complex intestinal disorders characterized by dysregulated innate and adaptive immune responses to gut microbiota in genetically susceptible hosts.

Inflammatory bowel disease (IBD) is typically categorized as Crohn’s disease or ulcerative colitis (UC) on the basis of anatomic, clinical, and histopathologic criteria. Dysregulated human gut B and T lymphocytes contribute to the immunopathogenesis of UC, a type of IBD characterized by mucosal damage in the colon.

A large team of medical scientists led by those at the University of California at San Diego (La Jolla, CA, USA) obtained intestinal biopsies and peripheral blood from patients undergoing colonoscopy at their facilities. Cells were recovered, washed, filtered, and used for mass cytometry by time of flight (CyTOF, Fluidigm, South San Francisco, CA, USA) or labeled with anti-human CD45 for sorting. CD45+ immune cells were sorted on a FACSAria II (BD Biosciences, San Jose, CA, USA). Intestinal biopsies were mechanically dissociated, then placed into a digestion mixture, filtered, and stained with anti-human CD45. CD45+ immune cells were sorted on a FACSAria II. About 20,000 sorted CD45+ cells were loaded and partitioned into Gel Bead In-Emulsions. Single-cell RNA (scRNA) libraries were sequenced on a HiSeq 4000 (Illumina, San Jose, CA, USA).

The investigators found a suite of ulcerative colitis-related immune cell shifts and clonal relationships, from clonal B cell receptor clonotype clusters and an uptick in plasma cells expressing immunoglobulin G1 to a rise in ZEB2 transcription factor-expressing regulatory T cells in colon tissue. The resulting single-cell sequencing resource revealed heterogeneity among tissue-resident memory T cells (TRM) in UC, including expansion of an inflammatory CD8+ TRM subset expressing the Eomesodermin transcription factor.

The team also flagged informative transcriptional features in CD8+ tissue-resident memory T cells typically tasked with buffeting bacterial infections, defining a handful of transcriptionally distinct clusters of the cells in colon tissue that differed from healthy tissue to tissue affected by ulcerative colitis, including a cluster with more inflamed versions of the CD8+ tissue-resident T cells.

The authors concluded that their study identified alterations in immune cell types and clonal relationships that occur in the context of disease, including plasma cells, Treg cells, γδ T cells, and CD8+ TRM cells, and will enable other investigators to identify additional UC-associated changes in a cell type– and tissue-specific manner for further study. The study was published on August 21, 2020 in the journal Science Immunology.

Related links:
University of California at San Diego
Fluidigm
BD Biosciences
Illumina



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.